NEW YORK, NY / ACCESSWIRE / May 16, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Vroom, Inc. (NASDAQ:VRM)
Class Period: June 9, 2020 - March 3, 2021
Lead Plaintiff Deadline: May 21, 2021
The VRM lawsuit alleges Vroom, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Vroom had not demonstrated that it was able to control and scale growth in respect to its salesforce to meet the demand for its products; (2) as a result, the Company was forced to discount aged inventory to move through its retail channels or liquidated in its wholesale channels; (3) as a result, the ecommerce gross profit per unit was reasonably likely to decline; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in VRM: http://www.kleinstocklaw.com/pslra-1/vroom-inc-loss-submission-form?id=15909&from=1
Canoo Inc. (NASDAQ:GOEV)
Class Period: August 18, 2020 - March 29, 2021
Lead Plaintiff Deadline: June 1, 2021
The GOEV lawsuit alleges that Canoo Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's engineering services was not a viable business, would not provide meaningful revenue in 2021, and would not reduce operational risk; (ii) the Company would no longer be focused on its subscription-based business model; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in GOEV: http://www.kleinstocklaw.com/pslra-1/canoo-inc-loss-submission-form?id=15909&from=1
ChemoCentryx, Inc. (NASDAQ:CCXI)
Class Period: November 26, 2019 - May 3, 2021
Lead Plaintiff Deadline: July 6, 2021
According to the complaint, ChemoCentryx, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in CCXI: http://www.kleinstocklaw.com/pslra-1/chemocentryx-inc-loss-submission-form?id=15909&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm